EP0471890B1 - Sterile filtered colostrum - Google Patents
Sterile filtered colostrum Download PDFInfo
- Publication number
- EP0471890B1 EP0471890B1 EP90124315A EP90124315A EP0471890B1 EP 0471890 B1 EP0471890 B1 EP 0471890B1 EP 90124315 A EP90124315 A EP 90124315A EP 90124315 A EP90124315 A EP 90124315A EP 0471890 B1 EP0471890 B1 EP 0471890B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- sterile
- colostrum
- filtered
- colostral
- milk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000003022 colostrum Anatomy 0.000 title claims abstract 15
- 235000021277 colostrum Nutrition 0.000 title claims abstract 15
- 239000005018 casein Substances 0.000 claims abstract description 29
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 29
- 235000021240 caseins Nutrition 0.000 claims abstract description 29
- 238000001914 filtration Methods 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims description 17
- 239000012528 membrane Substances 0.000 claims description 11
- 238000011146 sterile filtration Methods 0.000 claims description 11
- 241000894006 Bacteria Species 0.000 claims description 7
- 238000005352 clarification Methods 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- 241000283690 Bos taurus Species 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 238000003916 acid precipitation Methods 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 238000010306 acid treatment Methods 0.000 abstract description 2
- 235000013336 milk Nutrition 0.000 description 40
- 239000008267 milk Substances 0.000 description 40
- 210000004080 milk Anatomy 0.000 description 40
- 235000020183 skimmed milk Nutrition 0.000 description 22
- 239000000243 solution Substances 0.000 description 11
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 229940072221 immunoglobulins Drugs 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 244000052616 bacterial pathogen Species 0.000 description 6
- 208000018522 Gastrointestinal disease Diseases 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000011026 diafiltration Methods 0.000 description 5
- 239000005862 Whey Substances 0.000 description 4
- 102000007544 Whey Proteins Human genes 0.000 description 4
- 108010046377 Whey Proteins Proteins 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 238000009928 pasteurization Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011118 depth filtration Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000000369 enteropathogenic effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 230000000945 opiatelike Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
- A23C9/206—Colostrum; Human milk
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
- A23C9/142—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
- A23C9/1422—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration by ultrafiltration, microfiltration or diafiltration of milk, e.g. for separating protein and lactose; Treatment of the UF permeate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0017—Filtration
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C2210/00—Physical treatment of dairy products
- A23C2210/20—Treatment using membranes, including sterile filtration
- A23C2210/208—Removal of bacteria by membrane filtration; Sterile filtration of milk products
Definitions
- the invention relates to the colostral milk characterized in more detail in the claims and to a method for the production thereof.
- Colostral milk from cattle which was taken in the first 30 hours after calving, contains a high concentration of IgG, IgA and IgM and is also optimally suited in its other protein composition, making the calves passive in the first days after birth To confer immunity specifically against enteropathogenic germs.
- This property of colostral milk has led to the development of several methods for isolating the colostral milk immunoglobulins and using them for a therapy specifically for gastrointestinal disorders in humans.
- DE-C-2 813 984, DE-C-3 432 718, EP-B-102 831 and US-A-4 051 235, US-A-4 784 850 and US-A-4 834 974 describe them Production of preparations containing immunoglobulin from colostral milk. In addition to the immunoglobulins, some of these preparations also contain other proteins. However, all preparations have in common that they have been produced from colostral whey after the casein has been previously precipitated and separated off by acid precipitation or enzymatic processes. The separation of the casein is necessary in all cases in which the colostral milk is either to be sterile filtered or ultrafiltered.
- Beef colostral milk has a protein concentration of around 12% and contains a large number of bacteria in addition to cellular particles.
- the germ content in the raw colostral milk is 106 - 108 germs per ml, compared to 103 - 104 germs per ml in normal cow's milk.
- pasteurization e.g. For 15 to 40 seconds at 71 - 74 ° C or for 1 to 4 seconds at 85 - 90 ° C the pathogenic germs can be reduced by 1-2 powers of ten, but the milk is still very heavily contaminated with bacteria.
- these or newly introduced germs can multiply again and, particularly when the colostral milk is used therapeutically for gastrointestinal disorders, can lead to serious side effects.
- US-A-3 911 108 describes the sterilization of colostral milk and its derivatives with ⁇ -PL. Another method is e.g. represents the gamma radiation of colostral milk. However, both methods lead to a partial denaturation of the proteins.
- US-A-4 140 806 describes the filtration of normal milk to separate the fat and at the same time sterilize the filtrate.
- this milk has a fundamentally different protein and fat composition than colostral milk, which also has a significantly higher germ load.
- GB-A-2 052 979 teaches the sterilization of defatted colostral milk by ionizing radiation. While the pathogenic bacteria are completely separated by sterile filtration, the bacterial killing caused by radiation leads to the milk then containing more toxins and cell components of the bacteria.
- EP-A-0 046 909 describes a colostral milk from cows immunized during pregnancy, in which bacteria and fat are separated by centrifugation. Completely germ-free milk cannot be obtained by centrifugation.
- DE-C-2 813 984 expressly points out that skimming and clarification (casein precipitation) must be carried out very far in order to avoid subsequent clogging of the filters and ultrafilters.
- the aim of the invention was therefore to develop a method for removing the bacteria from colostral milk by sterile filtration in which as far as possible all of the protein components of the original colostral milk are retained.
- colostral milk can be clarified and sterile filtered without first removing the casein fraction if the possibly defatted colostral milk is acidified to a pH below 3.5.
- the casein precipitates at pH 4 to 5, but is brought back into solution by the further lowering of the pH.
- the properties of this acidic solution have changed so far compared to that of colostral milk that it can now be sterile filtered.
- the colostral milk acidified in this way can also be reset to its initial pH value before filtration.
- the casein precipitates again at pH 4 to 5 and goes back into solution from about pH 5.5.
- the colostral skimmed milk obtained in this way is surprisingly even somewhat easier to filter than the acidic colostral skimmed milk with a pH of less than 3.5.
- a preferred embodiment of the invention consists in degreasing colostral milk by measures known per se and diluting it with NaCl solution to a protein content of 20 g / l.
- the pH of the colostral skimmed milk is adjusted to pH 2.0 to 3.5, preferably 2.8 to 3.2, until the precipitate formed during acidification is dissolved again.
- the temperature during the acid treatment should not exceed 45 ° C to avoid denaturing the immunoglobulins.
- the pH is adjusted to the original value of the colostral skim milk again immediately or after some time with sodium hydroxide solution.
- the casein temporarily precipitates again and immediately goes into solution again.
- the colostral skimmed milk subjected to this treatment can now be easily sterile filtered or ultrafiltered using the known methods.
- the colostral skimmed milk can be clarified using a depth filter.
- the colostral skimmed milk clarified in this way can then be sterile filtered through membrane or depth filters.
- Ultrafiltration or diafiltration of the colostral skimmed milk treated according to the invention is also possible before or after sterile filtration.
- the filterability can be further improved if filter aids such as e.g. Hyflo Supercell R used in filtration.
- the sterile-filtered colostral skimmed milk is preferably adjusted to a protein content of 20 to 70 g / l, but can also be concentrated to 120 g / l.
- the concentration of lactose can be reduced by diafiltration and the ionic environment can be adjusted in such a way that the preparation obtained is particularly suitable for therapeutic use in gastrointestinal disorders.
- the sterile-filtered colostral skimmed milk can also be freeze-dried or fractionated into its protein components.
- the filtration is preferably carried out with the defatted colostral skimmed milk
- the method according to the invention is also suitable for non-defatted colostral milk.
- the filtration rate is significantly lower than that of colostral skimmed milk, but it is still much better than that of non-acid-treated colostral milk.
- the pH was adjusted to 3.0 within 30 seconds using 1 N hydrochloric acid. After an hour, the solution (approx. 3 l) was clarified with a pressure of 0.5 bar through a depth filter with a filter area of 150 cm2 (Supra 80 from Seitz). Following the clarification filtration, sterile filtration was carried out using a membrane filter combination with 5 ⁇ / 1.2 ⁇ / 0.65 ⁇ / 0.22 ⁇ membranes.
- the colostral milk was degreased and diluted in the same way, but without acidifying to pH 3.0. Only 150 ml of this colostral skimmed milk could be filtered through the depth filter under high pressure at 3 bar. Sterile filtration through membrane filters was not possible.
- Example 1 500 ml of colostral milk were acidified to pH 3.0 as in Example 1. After two hours, the pH was adjusted to 6.5 and was clarified and sterile filtered in the same way as in Example 1. This time it was possible to filter through the depth filter at a pressure of 0.2 bar.
- Example 2 500 ml of colostral milk were treated as in Example 2 and filtered.
- 3 g of filter aid Hyflo Supercell
- This addition improved the filtration rate in deep filtration. It was then sterile filtered as in Example 1.
- a control preparation of colostral skimmed milk without acidification to pH 3.0 as in example 1 could be clarified after adding the filter aid at a pressure of 1 bar through the Supra 80 depth filter. Sterile filtration through membrane filters was not possible.
- Example 2 500 ml of colostral milk were degreased as in Example 1 and then adjusted to pH 2.8 undiluted. The pH was then adjusted to 6.5 again. The colostral skimmed milk was clarified through Supra 80 depth filters with the addition of 3% filter aid and then sterile filtered through EK 1 filters (Seitz).
- the permeate flow rate for the colostral skim milk treated according to the invention was 11 l per hour and m2 membrane area at a transmembrane pressure of 1.2 bar.
- the colostral skimmed milk was concentrated to a protein content of 110 g per liter.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Nutrition Science (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Water Supply & Treatment (AREA)
- Molecular Biology (AREA)
- Dairy Products (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Die Erfindung betrifft die in den Ansprüchen näher gekennzeichnete Kolostral-Milch und ein Verfahren zu ihrer Herstellung.The invention relates to the colostral milk characterized in more detail in the claims and to a method for the production thereof.
Kolostral-Milch vom Rind, die in den ersten 30 Stunden nach dem Kalben entnommen wurde, enthält eine hohe Konzentration an IgG, IgA und IgM und ist auch in ihrer sonstigen Proteinzusammensetzung optimal dafür geeignet, den Kälbern in den ersten Tagen nach der Geburt eine passive Immunität speziell gegen enteropathogene Keime zu verleihen. Diese Eigenschaft der Kolostral-Milch hat dazu geführt, daß mehrere Verfahren entwickelt wurden, die Kolostralmilch-Immunglobuline zu isolieren und für eine Therapie speziell von gastrointestinalen Störungen beim Menschen zu verwenden.Colostral milk from cattle, which was taken in the first 30 hours after calving, contains a high concentration of IgG, IgA and IgM and is also optimally suited in its other protein composition, making the calves passive in the first days after birth To confer immunity specifically against enteropathogenic germs. This property of colostral milk has led to the development of several methods for isolating the colostral milk immunoglobulins and using them for a therapy specifically for gastrointestinal disorders in humans.
So beschreiben z.B. DE-C-2 813 984, DE-C-3 432 718, EP-B-102 831 und US-A-4 051 235, US-A-4 784 850 und US-A-4 834 974 die Herstellung von immunglobulinhaltigen Präparaten aus KolostralMilch. Diese Präparate enthalten neben den Immunglobulinen teilweise noch andere Proteine. Allen Präparaten gemeinsam ist aber, daß sie aus Kolostral-Molke hergestellt worden sind, nachdem zuvor das Casein durch Säurefällung oder enzymatische Prozesse präzipitiert und abgetrennt worden ist. Die Abtrennung des Caseins ist in all den Fällen notwendig, in denen die Kolostral-Milch entweder sterilfiltriert oder ultrafiltriert werden soll.For example, DE-C-2 813 984, DE-C-3 432 718, EP-B-102 831 and US-A-4 051 235, US-A-4 784 850 and US-A-4 834 974 describe them Production of preparations containing immunoglobulin from colostral milk. In addition to the immunoglobulins, some of these preparations also contain other proteins. However, all preparations have in common that they have been produced from colostral whey after the casein has been previously precipitated and separated off by acid precipitation or enzymatic processes. The separation of the casein is necessary in all cases in which the colostral milk is either to be sterile filtered or ultrafiltered.
Kolostral-Milch vom Rind hat eine Proteinkonzentration von rund 12 % und enthält neben zellulären Partikeln eine hohe Zahl an Bakterien.Beef colostral milk has a protein concentration of around 12% and contains a large number of bacteria in addition to cellular particles.
Der Keimgehalt in der rohen Kolostral-Milch liegt bei 10⁶ - 10⁸ Keimen pro ml, im Vergleich zu 10³ - 10⁴ Keimen pro ml bei normaler Kuhmilch. Durch Pasteurisation z.B. für 15 bis 40 sec bei 71 - 74 °C oder für 1 bis 4 sec bei 85 - 90 °C läßt sich zwar der Gehalt an pathogenen Keimen um 1 - 2 Zehnerpotenzen reduzieren, die Milch bleibt aber immer noch sehr stark mit Bakterien belastet. Bei der Lagerung können sich diese oder neu eingetragene Keime wieder vermehren und besonders bei der therapeutischen Anwendung der Kolostral-Milch bei gastrointestinalen Störungen zu ernsten Nebenwirkungen führen.The germ content in the raw colostral milk is 10⁶ - 10⁸ germs per ml, compared to 10³ - 10⁴ germs per ml in normal cow's milk. By pasteurization e.g. For 15 to 40 seconds at 71 - 74 ° C or for 1 to 4 seconds at 85 - 90 ° C the pathogenic germs can be reduced by 1-2 powers of ten, but the milk is still very heavily contaminated with bacteria. During storage, these or newly introduced germs can multiply again and, particularly when the colostral milk is used therapeutically for gastrointestinal disorders, can lead to serious side effects.
In US-A-3 911 108 ist die Sterilisation von Kolostral-Milch und ihrer Derivate mit β-PL beschrieben. Eine andere Methode stellt z.B. die gamma-Bestrahlung der Kolostral-Milch dar. Beide Methoden führen aber zu einer teilweisen Denaturierung der Proteine.US-A-3 911 108 describes the sterilization of colostral milk and its derivatives with β-PL. Another method is e.g. represents the gamma radiation of colostral milk. However, both methods lead to a partial denaturation of the proteins.
US-A-4 140 806 beschreibt das Filtrieren von normaler Milch zum Abtrennen des Fettes und gleichzeitigem Sterilmachen des Filtrats. Diese Milch aber hat eine grundsätzlich andere Protein- und Fettzusammensetzung als Kolostral-Milch, die auch eine wesentlich höhere Keimbelastung aufweist.US-A-4 140 806 describes the filtration of normal milk to separate the fat and at the same time sterilize the filtrate. However, this milk has a fundamentally different protein and fat composition than colostral milk, which also has a significantly higher germ load.
GB-A-2 052 979 lehrt die Sterilisation entfetteter Kolostral-Milch durch ionisierende Strahlung. Während durch eine Sterilfiltration die pathogenen Bakterien komplett abgetrennt werden, führt die durch Bestrahlung bewirkte Abtötung von Bakterien dazu, daß die Milch dann vermehrt Toxine und Zellbestandteile der Bakterien enthält.GB-A-2 052 979 teaches the sterilization of defatted colostral milk by ionizing radiation. While the pathogenic bacteria are completely separated by sterile filtration, the bacterial killing caused by radiation leads to the milk then containing more toxins and cell components of the bacteria.
EP-A-0 046 909 beschreibt eine Kolostral-Milch von während der Trächtigkeit immunisierten Kühen, bei der durch Zentrifugieren Bakterien und Fett abgetrennt werden. Eine völlig keimfreie Milch ist durch Zentrifugieren aber nicht erhältlich.EP-A-0 046 909 describes a colostral milk from cows immunized during pregnancy, in which bacteria and fat are separated by centrifugation. Completely germ-free milk cannot be obtained by centrifugation.
Die einfachste, effektivste und proteinschonendste Methode zur Entfernung der Bakterien, die Sterilfiltration, ist mit Kolostral-Milch nicht möglich, weil insbesondere das Casein sofort den Filter verstopft. Aus diesem Grunde verwenden alle Verfahren, die zu einem sterilfiltrierbaren oder ultrafiltrierbarem Präparat gelangen wollen, die gegebenenfalls entfettete Molke als Ausgangsmaterial. Bei der Herstellung der Molke wird das Casein durch Säure- oder Enzymwirkung ausgefällt und durch Zentrifugation abgetrennt. Die resultierende Molke bzw. die aus ihr isolierten Fraktionen sind dann ultrafiltrierbar und sterilfiltrierbar.The simplest, most effective and most gentle method of removing bacteria, sterile filtration, is not possible with colostral milk, because the casein in particular immediately clogs the filter. For this reason, all processes that want to get a sterile-filterable or ultrafilterable preparation use the whey, if necessary, defatted as starting material. In the production of the whey, the casein is precipitated by the action of an acid or enzyme and separated off by centrifugation. The resulting whey or the fractions isolated from it can then be ultrafiltered and sterile filtered.
In DE-C-2 813 984 wird ausdrücklich darauf hingewiesen, daß die Entrahmung und Klärung (Caseinfällung) sehr weit getrieben werden muß, um eine nachfolgende Verstopfung der Filter und Ultrafilter zu vermeiden.DE-C-2 813 984 expressly points out that skimming and clarification (casein precipitation) must be carried out very far in order to avoid subsequent clogging of the filters and ultrafilters.
Die Entfernung des Caseins durch Präzipitation hat aber gravierende Nachteile für die weitere Verwendung bzw. Aufreinigung der Kolostral-Milch:
- 1. Durch Einschluß in den Niederschlag und Copräzipitation mit dem Casein kann der Verlust an Immunglobulinen bei diesem Schritt bis zu 40 % betragen.
- 2. Die Zentrifugation des Casein-Niederschlags ist ein aufwendiger Schritt, der um so aufwendiger wird, je mehr man auf die Ausbeute der Immunglobuline achtet.
- 3. Casein selbst hat günstige therapeutisch anwendbare Eigenschaften, die besonders die Wirkung der Immunglobuline bei gastrointestinalen Störungen unterstützen. So werden aus dem Casein opiatartige Wirkstoffe freigesetzt, die zur Hemmung der Darmbewegung und Förderung der Elektrolyt- und Wasserresorption führen. Diese Wirkungen werden auch dem intakten Casein zugeschrieben (Recker, B., Physis 1/89, 32).
- 1. By inclusion in the precipitate and coprecipitation with the casein, the loss of immunoglobulins in this step can be up to 40%.
- 2. The centrifugation of the casein precipitate is a complex step, which becomes more complex the more one pays attention to the yield of the immunoglobulins.
- 3. Casein itself has favorable therapeutically applicable properties, which particularly support the action of the immunoglobulins in gastrointestinal disorders. Thus, opiate-like active substances are released from the casein, which inhibit the movement of the intestine and promote the absorption of electrolytes and water. These effects are also attributed to intact casein (Recker, B., Physis 1/89, 32).
Generell wäre es wünschenswert, die Kolostral-Milch möglichst wenig in ihrer Proteinzusammensetzung zu verändern, da sie geradezu optimal für die Prophylaxe und Therapie von gastrointestinalen Infektionen und Störungen zusammengesetzt ist. So haben neben den Immunglobulinen und dem Casein andere Proteine wie Lysozym, Lactoferrin und Peroxydasen wichtige Funktionen bei der Abwehr bakterieller Infektionen. Ein Großteil dieser wichtigen Proteine werden bei der Casein-Fällung und der Pasteurisation aber abgetrennt oder inaktiviert.In general, it would be desirable to change the colostral milk as little as possible in its protein composition, since it is almost optimally composed for the prophylaxis and therapy of gastrointestinal infections and disorders. So In addition to immunoglobulins and casein, other proteins such as lysozyme, lactoferrin and peroxidases have important functions in the defense against bacterial infections. Most of these important proteins are separated or inactivated during casein precipitation and pasteurization.
Die Erfindung hatte deshalb zum Ziel, ein Verfahren zur Entfernung der Bakterien aus Kolostral-Milch durch Sterilfiltration zu entwickeln, bei dem möglichst alle Proteinbestandteile der ursprünglichen Kolostral-Milch weitgehend erhalten bleiben.The aim of the invention was therefore to develop a method for removing the bacteria from colostral milk by sterile filtration in which as far as possible all of the protein components of the original colostral milk are retained.
Es wurde nun überraschenderweise gefunden, daß man Kolostral-Milch klärfiltrieren und sterilfiltrieren kann, ohne vorher die Casein-Fraktion zu entfernen, wenn man die gegebenenfalls entfettete Kolostral-Milch auf einen pH-Wert von unter 3,5 ansäuert. Beim Herabsenken des pH-Werts fällt zwar das Casein bei pH 4 bis 5 aus, wird aber durch das weitere Absenken des pH-Werts wieder in Lösung gebracht. Diese saure Lösung ist in ihren Eigenschaften gegenüber der Kolostral-Milch soweit verändert, daß sie nun sterilfiltrierbar ist.It has now surprisingly been found that colostral milk can be clarified and sterile filtered without first removing the casein fraction if the possibly defatted colostral milk is acidified to a pH below 3.5. When the pH is lowered, the casein precipitates at pH 4 to 5, but is brought back into solution by the further lowering of the pH. The properties of this acidic solution have changed so far compared to that of colostral milk that it can now be sterile filtered.
Man kann die auf diese Weise angesäuerte Kolostral-Milch auch vor der Filtration wieder auf ihren Ausgangs-pH-Wert einstellen. Bei diesem Zurückstellen des pH-Werts fällt das Casein bei pH 4 bis 5 erneut aus und geht ab etwa pH 5,5 wieder in Lösung. Die so erhaltene Kolostral-Magerilch ist überraschenderweise sogar noch etwas besser filtrierbar als die saure Kolostral-Magermilch mit einem pH-Wert von unter 3,5.The colostral milk acidified in this way can also be reset to its initial pH value before filtration. When the pH value is reset, the casein precipitates again at pH 4 to 5 and goes back into solution from about pH 5.5. The colostral skimmed milk obtained in this way is surprisingly even somewhat easier to filter than the acidic colostral skimmed milk with a pH of less than 3.5.
Beim Herabsenken des pH-Wertes ist es wichtig, daß das Casein nur kurz in dem präzipierten Zustand verbleibt und der pH-Wert zügig weiter gesenkt wird, bis das Casein wieder in Lösung gebracht worden ist. Wenn der Casein-Niederschlag zu lange als Präzipitat vorliegt und erst nach längerer Zeit wieder in Lösung gebracht worden wird, wird die Filtrierbarkeit der Kolostral-Milch deutlich schlechter.When lowering the pH, it is important that the casein only remains briefly in the precipitated state and that the pH is rapidly reduced further until the casein has been brought back into solution. If the casein precipitate is present too long as a precipitate and is only brought back into solution after a long time, the filterability of the colostral milk becomes significantly worse.
Eine bevorzugte Ausführungsform der Erfindung besteht darin, daß man Kolostral-Milch durch an sich bekannte Maßnahmen entfettet und mit NaCl-Lösung auf einen Protein-Gehalt von 20 g/l verdünnt. Durch schnelle Zugabe von Salzsäure wird der pH-Wert der Kolostral-Magermilch auf pH 2,0 bis 3,5 vorzugsweise 2,8 bis 3,2 eingestellt, bis der bei der Ansäuerung entstandene Niederschlag wieder gelöst ist. Die Temperatur sollte bei der Säurebehandlung nicht über 45 °C liegen, um eine Denaturierung der Immunglobuline zu vermeiden.A preferred embodiment of the invention consists in degreasing colostral milk by measures known per se and diluting it with NaCl solution to a protein content of 20 g / l. By rapidly adding hydrochloric acid, the pH of the colostral skimmed milk is adjusted to pH 2.0 to 3.5, preferably 2.8 to 3.2, until the precipitate formed during acidification is dissolved again. The temperature during the acid treatment should not exceed 45 ° C to avoid denaturing the immunoglobulins.
Gegebenenfalls wird der pH-Wert sofort oder nach einiger Zeit wieder mit Natronlauge auf den ursprünglichen Wert der Kolostral-Magermilch eingestellt. Bei diesem Hochstellen des pH-Werts fällt das Casein zeitweilig wieder aus und geht sofort wieder in Lösung.If necessary, the pH is adjusted to the original value of the colostral skim milk again immediately or after some time with sodium hydroxide solution. When the pH is raised, the casein temporarily precipitates again and immediately goes into solution again.
Die dieser Behandlung unterzogene Kolostral-Magermilch kann nun mit den bekannten Methoden leicht sterilfiltriert oder ultrafiltriert werden. Zum Beispiel kann man die Kolostral-Magermilch über ein Tiefenfilter klärfiltrieren. Die auf solche Weise klärfiltrierte Kolostral-Magermilch kann dann über Membran- oder Tiefenfilter sterilfiltriert werden. Auch eine Ultrafiltration oder Diafiltration der erfindungsgemäß behandelten Kolostral-Magermilch vor oder nach der Sterilfiltration ist möglich.The colostral skimmed milk subjected to this treatment can now be easily sterile filtered or ultrafiltered using the known methods. For example, the colostral skimmed milk can be clarified using a depth filter. The colostral skimmed milk clarified in this way can then be sterile filtered through membrane or depth filters. Ultrafiltration or diafiltration of the colostral skimmed milk treated according to the invention is also possible before or after sterile filtration.
Die Filtrierbarkeit läßt sich weiter verbessern, wenn man Filterhilfsmittel wie z.B. Hyflo Supercell Ⓡ bei der Filtration verwendet.The filterability can be further improved if filter aids such as e.g. Hyflo Supercell Ⓡ used in filtration.
Die sterilfiltrierte Kolostral-Magermilch wird vorzugsweise auf einen Proteingehalt von 20 bis 70 g/l eingestellt, kann aber auch bis auf 120 g/l konzentriert werden. Durch Diafiltration kann die Konzentration der Laktose reduziert und das Ionenmilieu derart eingestellt werden, daß das erhaltene Präparat besonders für die therapeutische Anwendung bei gastrointestinalen Störungen geeignet ist. Die sterilfiltrierte Kolostral-Magermilch kann außerdem gefriergetrocknet oder in ihre Proteinbestandteile fraktioniert werden.The sterile-filtered colostral skimmed milk is preferably adjusted to a protein content of 20 to 70 g / l, but can also be concentrated to 120 g / l. The concentration of lactose can be reduced by diafiltration and the ionic environment can be adjusted in such a way that the preparation obtained is particularly suitable for therapeutic use in gastrointestinal disorders. The sterile-filtered colostral skimmed milk can also be freeze-dried or fractionated into its protein components.
Wenngleich die Filtration vorzugsweise mit der entfetteten Kolostral-Magermilch durchgeführt wird, eignet sich das erfindungsgemäße Verfahren auch für nicht entfettete Kolostral-Milch. Die Filtrationsrate ist zwar deutlich geringer als bei der Kolostral-Magermilch, aber immer noch wesentlich besser als bei der nicht säurebehandelten Kolostral-Milch.Although the filtration is preferably carried out with the defatted colostral skimmed milk, the method according to the invention is also suitable for non-defatted colostral milk. The filtration rate is significantly lower than that of colostral skimmed milk, but it is still much better than that of non-acid-treated colostral milk.
Die folgenden Beispiele sollen die Erfindung näher beschreiben.The following examples are intended to describe the invention in more detail.
500 ml gefrorene Kolostral-Milch wurden mit 500 ml Wasser versetzt und bei 37°C aufgetaut. Durch Zentrifugation wurde die Lipid-Fraktion abgetrennt und die so erhaltene Kolostral-Magermilch mit 2000 ml 100 mM NaCl-Lösung verdünnt.500 ml of frozen colostral milk were mixed with 500 ml of water and thawed at 37 ° C. The lipid fraction was separated by centrifugation and the colostral skimmed milk thus obtained was diluted with 2000 ml of 100 mM NaCl solution.
Mit 1 N Salzsäure wurde der pH-Wert innerhalb von 30 Sekunden auf pH 3,0 eingestellt. Nach einer Stunde wurde die Lösung (ca. 3 l) mit einem Druck von 0,5 bar über einen Tiefenfilter mit 150 cm² Filterfläche (Supra 80 der Fa. Seitz) klärfiltriert. Im Anschluß an die Klärfiltration wurde über eine Membranfilter-Kombination mit 5µ/1,2µ/0,65µ/0,22µ Membranen sterilfiltriert.The pH was adjusted to 3.0 within 30 seconds using 1 N hydrochloric acid. After an hour, the solution (approx. 3 l) was clarified with a pressure of 0.5 bar through a depth filter with a filter area of 150 cm² (Supra 80 from Seitz). Following the clarification filtration, sterile filtration was carried out using a membrane filter combination with 5µ / 1.2µ / 0.65µ / 0.22µ membranes.
Zum Vergleich wurde die Kolostral-Milch in gleicher Weise entfettet und verdünnt, allerdings ohne das Ansäuern auf pH 3,0. Von dieser Kolostral-Magermilch konnten über die Tiefenfilter nur 150 ml unter hohem Druck bei 3 bar filtriert werden. Eine Sterilfiltration über Membranfilter war nicht möglich.For comparison, the colostral milk was degreased and diluted in the same way, but without acidifying to pH 3.0. Only 150 ml of this colostral skimmed milk could be filtered through the depth filter under high pressure at 3 bar. Sterile filtration through membrane filters was not possible.
500 ml Kolostral-Milch wurden wie im Beispiel 1 auf pH 3,0 angesäuert. Nach zwei Stunden wurde der pH-Wert auf 6,5 eingestellt und in gleicher Weise wie in Beispiel 1 klär- und sterilfiltriert. Diesmal war die Filtration über den Tiefenfilter bei einem Druck von 0,2 bar möglich.500 ml of colostral milk were acidified to pH 3.0 as in Example 1. After two hours, the pH was adjusted to 6.5 and was clarified and sterile filtered in the same way as in Example 1. This time it was possible to filter through the depth filter at a pressure of 0.2 bar.
500 ml Kolostral-Milch wurden wie in Beispiel 2 behandelt und filtriert. Bei der Tiefenfiltration über Supra 80-Filter wurden 3 g Filterhilfsmittel (Hyflo Supercell) pro 100 ml verdünnte Kolostral-Magermilch zugesetzt. Dieser Zusatz verbesserte die Filtrationsrate bei der Tiefenfiltration. Anschließend wurde wie in Beispiel 1 sterilfiltriert.500 ml of colostral milk were treated as in Example 2 and filtered. In the case of depth filtration via Supra 80 filters, 3 g of filter aid (Hyflo Supercell) were added per 100 ml of diluted colostral skimmed milk. This addition improved the filtration rate in deep filtration. It was then sterile filtered as in Example 1.
Eine Kontroll-Präparation Kolostral-Magermilch ohne Ansäuern auf pH 3,0 wie in Beisiel 1 konnte nach Zusatz des Filterhilfsmittels bei einem Druck von 1 bar über den Supra 80 Tiefenfilter klärfiltriert werden. Die Sterilfiltration über Membranfilter war aber nicht möglich.A control preparation of colostral skimmed milk without acidification to pH 3.0 as in example 1 could be clarified after adding the filter aid at a pressure of 1 bar through the Supra 80 depth filter. Sterile filtration through membrane filters was not possible.
500 ml Kolostral-Milch wurden wie im Beispiel 1 entfettet und anschließend unverdünnt auf pH 2,8 eingestellt. Anschließend wurde der pH-Wert wieder auf 6,5 eingestellt. Die Kolostral-Magermilch wurde über Supra 80 Tiefenfilter unter Zusatz von 3 % Filterhilfsmittel klärfiltriert und anschließend über EK 1-Filter (Fa. Seitz) sterilfiltriert.500 ml of colostral milk were degreased as in Example 1 and then adjusted to pH 2.8 undiluted. The pH was then adjusted to 6.5 again. The colostral skimmed milk was clarified through Supra 80 depth filters with the addition of 3% filter aid and then sterile filtered through EK 1 filters (Seitz).
500 ml Kolostral-Milch wurden mit 2500 ml 80 mM NaCl-Lösung verdünnt und mit 1 N Salzsäure auf pH 3,1 eingestellt. Der pH-Wert wurde anschließend auf pH 7,0 eingestellt und die fetthaltige Kolostral-Milch über Supra 80 Tiefenfilter unter Zusatz von 3 % Filterhilfsmittel (Hyflo Supercell) klärfiltriert und anschließend über EK 1-Sterilfilter sterilfiltriert.500 ml of colostral milk were mixed with 2500 ml of 80 mM NaCl solution diluted and adjusted to pH 3.1 with 1 N hydrochloric acid. The pH was then adjusted to pH 7.0 and the fat-containing colostral milk was clarified through a Supra 80 depth filter with the addition of 3% filter aid (Hyflo Supercell) and then sterile filtered through an EK 1 sterile filter.
Obwohl die Filtrationsrate bei der Klär- und bei der Sterilfiltration schlechter war als mit der entfetteten Kolostral-Magermilch, ist doch eine Filtration mit entsprechend größerer Filterfläche möglich. Die nicht angesäuerte, nicht entfettete Kolostral-Milch war unter den gleichen Bedingungen nicht einmal über den Supra 80-Tiefenfilter zu filtrieren.Although the filtration rate for clarification and sterile filtration was worse than with degreased colostral skimmed milk, filtration with a correspondingly larger filter area is still possible. The non-acidified, non-defatted colostral milk could not even be filtered through the Supra 80 depth filter under the same conditions.
1 Liter der sterilfiltrierten Kolostral-Magermilch aus Beispiel 3 wurde über eine 10000 D-Membran mit einer Membranfläche von 0,9 m² gegen das 5-fache Volumen 80 mM NaCl-Lösung diafiltriert und anschließend über die gleiche Membran ultrafiltriert.1 liter of the sterile-filtered colostral skimmed milk from Example 3 was diafiltered over a 10,000 D membrane with a membrane area of 0.9 m² against 5 times the volume of 80 mM NaCl solution and then ultrafiltered over the same membrane.
Zum Vergleich wurde eine in gleicher Weise verdünnte, aber nicht angesäuerte Kolostral-Magermilch der gleichen Diafiltration und Ultrafiltration unterzogen.For comparison, a colostral skim milk diluted in the same way but not acidified was subjected to the same diafiltration and ultrafiltration.
Bei der gewählten Versuchsanordnung betrug die Permeat-Flußrate für die erfindungsgemäß behandelte Kolostral-Magermilch 11 l pro Stunde und m² Membranfläche bei einem Transmembrandruck von 1,2 bar. Bei der Ultrafiltration wurde die Kolostral-Magermilch auf einen Proteingehalt von 110 g pro l ankonzentriert.In the chosen test arrangement, the permeate flow rate for the colostral skim milk treated according to the invention was 11 l per hour and m² membrane area at a transmembrane pressure of 1.2 bar. During ultrafiltration, the colostral skimmed milk was concentrated to a protein content of 110 g per liter.
Bei der Vergleichs-Präparation stieg schon während der Diafiltration der Transmembrandruck innerhalb kurzer Zeit auf über 2 bar an, und die Flußrate nahm rapide ab. Wegen Verstopfung der Membran mußte die Diafiltration abgebrochen werden. Eine Ultrafiltration war erst gar nicht möglich.In the comparative preparation, the transmembrane pressure rose to over 2 bar within a short time during the diafiltration, and the flow rate decreased rapidly. The diafiltration had to be stopped because the membrane was blocked. Ultrafiltration was not possible at all.
Claims (13)
- Sterile-filtered colostrum, characterized in that- the natural casein content is not reduced or is only insignificantly reduced,- all bacteria have been separated out by sterile filtration, and- it has been acidified in a first step to a pH of less than 3.5 in order to redissolve the initially precipitated casein, and the resulting solution has then been sterile-filtered.
- Sterile-filtered colostrum according to Claim 1, characterized in that the colostrum originates from cows.
- Sterile-filtered colostrum according to Claim 1 or 2, characterized in that the colostrum has had the fat removed.
- Sterile-filtered colostrum according to one of Claims 1 to 3, characterized in that the protein content is 1 to 120 g per l.
- Sterile-filtered colostrum according to Claim 4, characterized in that the protein content is 1 to 50 g per l.
- Sterile-filtered colostrum according to one of Claims 1 to 5, characterized in that the lactose content is less than 100 mg per l.
- A method of preparing a sterile-filtered, casein-containing colostrum according to one of Claims 1 to 6, characterized in thata) the optionally diluted colostrum is acidified until the initially precipitated casein has redissolved, andb) the resulting solution is sterile-filtered.
- A method according to Claim 7, characterized in that the pH of the colostrum is adjusted to 2.5 - 3.5.
- A method according to Claim 7 or 8, characterized in that the pH is readjusted to 5.5 - 8 before filtration.
- A method according to one of Claims 7 to 9, characterized in that a clarification is carried out before the sterile filtration.
- A method according to one of Claims 7 to 10, characterized in that filter aids are added in the filtration.
- A method according to one of Claims 7 to 11, characterized in that the fat is removed from the colostrum before the acid precipitation.
- A method according to one of Claims 7 to 12, characterized in that the clarification and sterile filtration are carried out using depth-type or membrane filters.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4026365 | 1990-08-21 | ||
DE4026365A DE4026365A1 (en) | 1990-08-21 | 1990-08-21 | STERILE FILTERED COLORED MILK |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0471890A1 EP0471890A1 (en) | 1992-02-26 |
EP0471890B1 true EP0471890B1 (en) | 1994-10-19 |
Family
ID=6412593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP90124315A Expired - Lifetime EP0471890B1 (en) | 1990-08-21 | 1990-12-15 | Sterile filtered colostrum |
Country Status (5)
Country | Link |
---|---|
US (1) | US5147548A (en) |
EP (1) | EP0471890B1 (en) |
JP (1) | JPH06121637A (en) |
AT (1) | ATE112937T1 (en) |
DE (2) | DE4026365A1 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4326665C2 (en) | 1993-08-09 | 1995-07-13 | Biotest Pharma Gmbh | Process for sterile filtration of milk |
FI97269B (en) * | 1993-10-12 | 1996-08-15 | Viable Bioproducts Ltd | Process for the production of nutritional beverages |
DE4337654C2 (en) * | 1993-11-04 | 1996-08-08 | Biotest Pharma Gmbh | Use of bovine colostral milk from animals not hyperimmunized with viruses as a liver protection preparation |
US5707678A (en) * | 1995-04-12 | 1998-01-13 | Galagen Inc. | Method for microfiltration of milk or colostral whey |
US5670196A (en) * | 1995-04-12 | 1997-09-23 | Galagen Inc. | Method for microfiltration of milk or colostral whey |
DE19619990A1 (en) * | 1996-05-17 | 1997-11-20 | Charlotte Adler | Process for the production of colostral milk products and their use |
WO1998053836A1 (en) * | 1997-05-27 | 1998-12-03 | Anderson Michael R | Improved gelled oxygen products |
EP1075190B1 (en) | 1998-04-29 | 2005-06-22 | Fonnelop, Kare | A process for the preparation of colostrum |
US6258383B1 (en) * | 1998-08-14 | 2001-07-10 | Lactoferrin Products Company | Dietary supplement combining colostrum and lactoferrin in a mucosal delivery format |
FI110752B (en) | 1999-05-25 | 2003-03-31 | Novatreat Oy | A method for treating colostrum |
SE0003045D0 (en) * | 2000-08-29 | 2000-08-29 | Probi Ab | New method |
KR20020021908A (en) * | 2000-09-18 | 2002-03-23 | 허강칠 | Healthful auxiliary food Made from Whey |
FI20010020A0 (en) * | 2001-01-05 | 2001-01-05 | Eino Elias Hakalehto | Milk - based product, its use and method of preparation |
DE10158009A1 (en) | 2001-11-21 | 2003-05-28 | Begerow E Gmbh & Co | Reducing total germination index in aqueous dispersions e.g. animal milk, involves carrying out sterile filtration using deep filtration units |
US20040226888A1 (en) * | 2003-05-14 | 2004-11-18 | Chandarana Dilip I. | Two stage sterilization of fluids that naturally support microbiological growth |
US20070065518A1 (en) * | 2003-10-22 | 2007-03-22 | Harry Leneau | Colostrum compositions and methods |
US8252341B2 (en) * | 2004-09-14 | 2012-08-28 | Paul Brazeau | Isolation of growth and differentiating factors from colostrum |
WO2006029494A1 (en) * | 2004-09-14 | 2006-03-23 | Nexcell Biosciences Inc. | Extraction of growth and differentiating factors from colostrum |
BRPI0721321A2 (en) * | 2007-02-20 | 2013-01-08 | Nutricia Nv | use of colostrum and composition |
WO2009092383A2 (en) * | 2008-01-22 | 2009-07-30 | Multimerics Aps | Products and methods to prevent infection |
CN106387045A (en) * | 2016-09-18 | 2017-02-15 | 济南大学 | Hot water pasteurization device of fresh milk and automatic control method thereof |
US10385094B2 (en) | 2017-07-26 | 2019-08-20 | Dustin Kjelden | Colostrum solid extraction process |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0046909A2 (en) * | 1980-08-29 | 1982-03-10 | Sendai Institute Of Microbiology | Pharmaceutical composition |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3911108A (en) | 1973-02-14 | 1975-10-07 | Diamond Shamrock Corp | Process of producing bovine milk products containing specific antibodies |
US4140806A (en) | 1975-02-27 | 1979-02-20 | Alfa-Laval Ab | Filtering method for separating skim milk from milk products |
US4051235A (en) * | 1976-04-22 | 1977-09-27 | Plymate Robert R | Method of preparing bovine colostrum for use in treating livestock |
CH627079A5 (en) * | 1977-04-15 | 1981-12-31 | Nestle Sa | Process for preparing a protein concentrate containing immunological factors of milk origin |
FR2460135A1 (en) | 1979-07-02 | 1981-01-23 | Liotet Serge | COMPOSITION FOR EXTERNAL USE BASED ON COLOSTRUM |
EP0052862B1 (en) * | 1980-11-26 | 1984-06-13 | COMPAGNIE GENERALE D'ELECTRICITE Société anonyme dite: | Sterilization device for a liquid |
NZ205392A (en) * | 1982-09-02 | 1987-03-06 | Unilever Plc | Preparation of immunoglobulins against e.coli pili |
DE3432718C1 (en) * | 1984-09-06 | 1986-05-22 | Biotest Pharma GmbH, 6000 Frankfurt | Process for the preparation of a solution of milk and / or colostral immunoglobulins |
SE451791B (en) * | 1984-09-11 | 1987-11-02 | Alfa Laval Food & Dairy Eng | SET AND PLANT FOR PREPARING MILK WITH LOW BACTERIA CONTENT |
US4834974A (en) * | 1986-01-13 | 1989-05-30 | Protein Technologies, Inc. | Immunologically active whey fraction and recovery process |
US4784850A (en) * | 1985-09-04 | 1988-11-15 | Mutzarei Maabarot | Process for preparing antibodies against E. Coli K-99 antigen from bovine milk |
DE3743440A1 (en) * | 1987-12-21 | 1989-06-29 | Gauri Kailash Kumar | METHOD FOR SEPARATING THE SOLVED AND UNSOLVED INGREDIENTS OF MILK |
FR2628973B1 (en) * | 1988-03-25 | 1990-11-16 | Gattefosse Ets Sa | COSMETIC OR PHARMACEUTICAL COMPOSITION FOR SKIN USE, AND PROCESS FOR THE PREPARATION OF SUCH A COMPOSITION |
US4897465A (en) * | 1988-10-12 | 1990-01-30 | Abbott Laboratories | Enrichment and concentration of proteins by ultrafiltration |
-
1990
- 1990-08-21 DE DE4026365A patent/DE4026365A1/en active Granted
- 1990-12-15 EP EP90124315A patent/EP0471890B1/en not_active Expired - Lifetime
- 1990-12-15 AT AT90124315T patent/ATE112937T1/en not_active IP Right Cessation
- 1990-12-15 DE DE59007518T patent/DE59007518D1/en not_active Expired - Fee Related
-
1991
- 1991-08-14 US US07/745,036 patent/US5147548A/en not_active Expired - Fee Related
- 1991-08-20 JP JP3208086A patent/JPH06121637A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0046909A2 (en) * | 1980-08-29 | 1982-03-10 | Sendai Institute Of Microbiology | Pharmaceutical composition |
Also Published As
Publication number | Publication date |
---|---|
DE4026365A1 (en) | 1992-02-27 |
EP0471890A1 (en) | 1992-02-26 |
JPH06121637A (en) | 1994-05-06 |
ATE112937T1 (en) | 1994-11-15 |
DE59007518D1 (en) | 1994-11-24 |
DE4026365C2 (en) | 1993-04-22 |
US5147548A (en) | 1992-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0471890B1 (en) | Sterile filtered colostrum | |
EP0638242B1 (en) | Method for sterilizing milk by filtration | |
DE69625477T2 (en) | METHOD FOR THE MICROFILTRATION OF MILK, WHEY, COLORED OR COLORED MOLKE | |
DE3689717T2 (en) | Egg-specific antibody-containing substance, process for its production and use. | |
EP0173999B1 (en) | Process for preparing a solution of milk and/or colostrum immunoglobins | |
DE69326054T2 (en) | Anticariogenic food | |
DE69220374T2 (en) | Process for the production of alpha-lactalbumin and beta-lactoglobulin from a whey protein product | |
DE60016668T2 (en) | Method for the treatment of colostrum | |
DE2458327A1 (en) | BOVINE IMMUNOGLOBULIN ISOLATION PROCEDURE | |
DE60311106T2 (en) | Process for the isolation of milk proteins and isolate of milk proteins | |
DE2333883A1 (en) | METHOD OF PRODUCING CLEANED ALBUMIN BY APPLICATION OF THERMOCOAGULATION AND THE OBTAINED CLEANED ALBUMIN | |
DE3402647C2 (en) | Process for the recovery of colony stimulating factor and kallikrein from human urine | |
DE1810438A1 (en) | Prophylactic or therapeutic preparation | |
DE69733097T2 (en) | Means for improving bone formation and inhibiting bone resorption | |
DE69426826T2 (en) | NUTRITIONAL DRINK | |
WO1989005586A1 (en) | Process for separating the dissolved and undissolved constituents of milk | |
EP0457370A1 (en) | Method for the pasteurization of the tissue protein PP4 | |
EP0918464B1 (en) | Process for production of colostral milk products and use thereof | |
DE69507613T2 (en) | METHOD FOR THE FRACTIONATION OF Whey Ingredients | |
EP0652013A1 (en) | Use of bovine colostrum as a preparation for liver | |
DE2857532C1 (en) | Therapeutic agent for wound treatment and process for its manufacture | |
WO1998016558A1 (en) | METHOD FOR PRODUCING AN IgM PREPARATION FOR INTRAVENOUS ADMINISTRATION | |
DE60216906T2 (en) | ANTI-PILYROSPORUM OVALE IGY AND ITS USE | |
DE60116982T2 (en) | Use of a mare's milk fraction selected from skimmed milk, whey and sodium caseinate with anti-inflammatory action | |
DE69924746T2 (en) | PROCESS FOR PRODUCING PROTEIN MATERIAL |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
17P | Request for examination filed |
Effective date: 19920319 |
|
17Q | First examination report despatched |
Effective date: 19920525 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT CH DE FR GB IT LI |
|
REF | Corresponds to: |
Ref document number: 112937 Country of ref document: AT Date of ref document: 19941115 Kind code of ref document: T |
|
ITF | It: translation for a ep patent filed | ||
REF | Corresponds to: |
Ref document number: 59007518 Country of ref document: DE Date of ref document: 19941124 |
|
GBT | Gb: translation of ep patent filed (gb section 77(6)(a)/1977) |
Effective date: 19941103 |
|
ET | Fr: translation filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19981209 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 19981214 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 19981218 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19981221 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19981223 Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19991215 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19991215 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19991231 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19991231 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 19991215 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20000831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20001003 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20051215 |